Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Immunomodulatory therapies for osteoarthritis: from bench to bedside

Jiao S., Elseaidy TA., Poehling G., Trasolini N., Bolander J.

Narrative Review on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Immune Modulation, published in Ann Jt (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Ann Jt (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42181596
PMCID
PMC13190628
DOI
10.21037/aoj-25-68

Abstract (original English)

Osteoarthritis (OA) of the knee, particularly in the medial compartment, is driven by chronic synovial inflammation, immune dysregulation, and progressive cartilage degeneration. Increasing evidence indicates that modifying the complete inflammatory microenvironment of the joint, rather than focusing solely on cartilage, is essential for achieving true disease-modifying outcomes. This review provides an integrated bench-to-bedside overview of emerging immunomodulatory cell and cell-derived therapies for knee OA, summarizing mechanistic foundations, preclinical findings, and early clinical progress. We first outline the pathological features of the OA joint, emphasizing macrophage polarization, T-cell subsets, and cytokine-driven pathways that sustain synovitis and extracellular matrix breakdown. The review then highlights three major therapeutic strategies: (I) immunomodulatory cell therapies, including cartilage-activated T cells (CATs), which aim to restore immune homeostasis; (II) extracellular vesicle (EV) and miRNA-based therapies that modulate inflammation, enhance chondrocyte survival, and promote matrix synthesis; and (III) peripheral blood stem cell (PBSC)-assisted regenerative approaches used in combination with arthroscopic procedures. Preclinical studies consistently demonstrate reduced inflammation, improved chondrogenesis, and enhanced structural repair across the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research